Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

Soldiers wear triangle masks and enforce the rules, often using weapons. Viewers see more of their actions this season, including their role as snipers. Managers, the highest-ranking staff, wear ...

Officials in New York City are urging people to consider wearing a face mask on public transport. Experts say the surge in winter infections is being driven by increased mixing over the holiday ...

Rush University Medical Center, in a note on its website, said visitors and staff must wear hospital-approved masks in some areas, citing increased levels of COVID-19 and other respiratory ...

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...